CN103492384B - 作为trk抑制剂的化合物和组合物 - Google Patents
作为trk抑制剂的化合物和组合物 Download PDFInfo
- Publication number
- CN103492384B CN103492384B CN201280019867.0A CN201280019867A CN103492384B CN 103492384 B CN103492384 B CN 103492384B CN 201280019867 A CN201280019867 A CN 201280019867A CN 103492384 B CN103492384 B CN 103492384B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- fluorophenyl
- disease
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1C[C@@](C)C(*)C1 Chemical compound CC1C[C@@](C)C(*)C1 0.000 description 10
- AGXKKIQEEVZOCF-NUHJPDEHSA-N C=[I]c1cc(C(C2)NC[C@H]2F)cc(C#N)c1 Chemical compound C=[I]c1cc(C(C2)NC[C@H]2F)cc(C#N)c1 AGXKKIQEEVZOCF-NUHJPDEHSA-N 0.000 description 1
- FSVWMTXMYKZYTA-HNNQXCQYSA-N CC(C)(C)/S(/O)=[O]\N[C@H](CCCO)c1cc(C#N)cc(F)c1 Chemical compound CC(C)(C)/S(/O)=[O]\N[C@H](CCCO)c1cc(C#N)cc(F)c1 FSVWMTXMYKZYTA-HNNQXCQYSA-N 0.000 description 1
- DBDIESYJMBSCPN-MDZDMXLPSA-N CC/C(/C(OCC)=O)=C(/C=C(C=C1)Br)\N1N Chemical compound CC/C(/C(OCC)=O)=C(/C=C(C=C1)Br)\N1N DBDIESYJMBSCPN-MDZDMXLPSA-N 0.000 description 1
- PQSLEXQFVUMCTQ-LLVKDONJSA-N CS(/[O]=C(\C1)/CN[C@H]1c1cccc(F)c1)(=O)=O Chemical compound CS(/[O]=C(\C1)/CN[C@H]1c1cccc(F)c1)(=O)=O PQSLEXQFVUMCTQ-LLVKDONJSA-N 0.000 description 1
- COKHMUBYEFXMPJ-VUWPPUDQSA-N N#Cc1cc(F)cc(C(C2)NC[C@H]2F)c1 Chemical compound N#Cc1cc(F)cc(C(C2)NC[C@H]2F)c1 COKHMUBYEFXMPJ-VUWPPUDQSA-N 0.000 description 1
- QNPMWTXQQSWIHE-UHFFFAOYSA-N NC(c1cc(C#N)cc(F)c1)=O Chemical compound NC(c1cc(C#N)cc(F)c1)=O QNPMWTXQQSWIHE-UHFFFAOYSA-N 0.000 description 1
- LJSGVSRHSBHOAJ-JFUPDXTOSA-N OC(c1c(cc(CC(CC(C2)c3cccc(F)c3)C[C@H]2F)cc2)[n]2nc1)=O Chemical compound OC(c1c(cc(CC(CC(C2)c3cccc(F)c3)C[C@H]2F)cc2)[n]2nc1)=O LJSGVSRHSBHOAJ-JFUPDXTOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446572P | 2011-02-25 | 2011-02-25 | |
| US61/446,572 | 2011-02-25 | ||
| PCT/US2012/026377 WO2012116217A1 (en) | 2011-02-25 | 2012-02-23 | Compounds and compositions as trk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103492384A CN103492384A (zh) | 2014-01-01 |
| CN103492384B true CN103492384B (zh) | 2016-05-11 |
Family
ID=45815979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280019867.0A Expired - Fee Related CN103492384B (zh) | 2011-02-25 | 2012-02-23 | 作为trk抑制剂的化合物和组合物 |
Country Status (28)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| KR20140105508A (ko) | 2011-12-12 | 2014-09-01 | 닥터 레디스 레보러터리즈 리미티드 | 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘 |
| EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
| PL3087070T3 (pl) * | 2013-12-26 | 2018-03-30 | Ignyta, Inc. | Pochodne pirazolo[1,5-a]pirydyny i sposoby ich zastosowania |
| CN109820853B (zh) * | 2014-02-05 | 2022-05-10 | Vm肿瘤药物有限责任公司 | 取代的杂环化合物在制备治疗癌症药物中的用途 |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| CN104529815B (zh) * | 2014-12-04 | 2016-08-24 | 宁波欧迅化学新材料技术有限公司 | 合成2,4-二硝基苯氧胺的方法 |
| US20180177792A1 (en) * | 2015-05-29 | 2018-06-28 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
| HK1253093A1 (zh) | 2015-06-01 | 2019-06-06 | Loxo Oncology Inc. | 诊断和治疗癌症的方法 |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| EP3490992B1 (en) | 2016-08-01 | 2023-03-22 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CA3031534C (en) | 2016-08-01 | 2023-10-17 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2017348826B2 (en) | 2016-10-28 | 2021-12-02 | Centaurus Biopharma Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
| CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| KR102619444B1 (ko) | 2017-08-23 | 2023-12-29 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| CA3108065C (en) | 2018-07-31 | 2025-10-07 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| WO2020187291A1 (zh) | 2019-03-19 | 2020-09-24 | 华中师范大学 | 吡唑并嘧啶化合物和药物组合物及其应用 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| BR112021022255A2 (pt) | 2019-05-08 | 2022-01-18 | Tyk Medicines Inc | Composto usado como inibidor de quinase e aplicação do mesmo |
| CN110804059B (zh) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | 氨基甲酸酯类化合物、药物组合物及其应用 |
| CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业(成都)有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
| IL294688A (en) * | 2020-01-22 | 2022-09-01 | Benevolentai Bio Ltd | Pharmaceutical compositions and their uses |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112779518B (zh) * | 2020-12-17 | 2022-07-22 | 东北师范大学 | 一种高发光强度的薄膜、制备方法及其用途 |
| CN112645955B (zh) * | 2020-12-24 | 2022-11-04 | 四川国康药业有限公司 | 一种[1,2,4]三唑并[4,3-b]哒嗪类化合物及其制备方法和用途 |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| CN117659005B (zh) * | 2022-08-26 | 2026-06-23 | 沈阳药科大学 | 一种吡唑并吡啶衍生物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2010048314A1 (en) * | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Family Cites Families (195)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| FI944549L (fi) | 1992-04-02 | 1994-11-30 | Smithkline Beecham Corp | Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| AR017457A1 (es) | 1998-02-14 | 2001-09-05 | Glaxo Group Ltd | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6495528B1 (en) | 1998-06-23 | 2002-12-17 | Smithkline Beecham Corporation | 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| KR100563395B1 (ko) | 1998-06-30 | 2006-03-23 | 다우 글로벌 테크놀로지스 인크. | 중합체 폴리올 및 이의 제조방법 |
| ES2264826T3 (es) | 1998-10-16 | 2007-01-16 | Pfizer Inc. | Derivados de adenina. |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PL200923B1 (pl) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| AU2001266100B9 (en) | 2000-06-27 | 2005-10-06 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derived from arylalkylamines |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| JP2002114788A (ja) * | 2000-08-03 | 2002-04-16 | Banyu Pharmaceut Co Ltd | カルバペネム誘導体の製造方法及び合成中間体 |
| CA2417826A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| SI1353919T1 (sl) | 2000-12-28 | 2006-12-31 | Almirall Prodesfarma Ag | Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo. |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| AR033290A1 (es) | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
| OA12609A (en) | 2001-05-25 | 2006-06-09 | Pfizer | An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. |
| EP1395604B1 (en) | 2001-06-12 | 2008-06-25 | Glaxo Group Limited | Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
| EP2039762A3 (en) | 2001-06-21 | 2009-07-29 | Verenium Corporation | Nitralases |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| RU2004110717A (ru) | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| AU2002359365B2 (en) | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| CA2470956C (en) | 2001-12-20 | 2011-08-02 | Laboratorios S.A.L.V.A.T., S.A. | 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| JP4324480B2 (ja) | 2002-03-26 | 2009-09-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメティクス、その製法、医薬組成物、及び使用 |
| WO2003086408A1 (en) | 2002-04-10 | 2003-10-23 | University Of Virginia Patent Foundation | Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
| WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ATE381535T1 (de) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | Phenethanolaminderivate |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| WO2004000814A1 (en) | 2002-06-25 | 2003-12-31 | Merck Frosst Canada & Co. | 8-(biaryl) quinoline pde4 inhibitors |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| US20060004056A1 (en) | 2002-07-02 | 2006-01-05 | Bernard Cote | Di-aryl-substituted-ethan pyridone pde4 inhibitors |
| WO2004005229A1 (en) | 2002-07-08 | 2004-01-15 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| HRP20050198A2 (hr) | 2002-08-10 | 2006-04-30 | Altana Pharma Ag | Piperidin-piridazoni i ftalazoni kao inhibitori pde4 |
| US20060166995A1 (en) | 2002-08-10 | 2006-07-27 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
| CA2495597A1 (en) | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
| AU2003263216A1 (en) | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Benzonaphthyridines with PDE 3/4 inhibiting activity |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1534675B1 (en) | 2002-08-23 | 2009-02-25 | Ranbaxy Laboratories, Ltd. | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists |
| CA2496459C (en) | 2002-08-29 | 2013-06-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| AU2003255493B8 (en) | 2002-08-29 | 2009-03-26 | Takeda Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
| NZ538932A (en) | 2002-08-29 | 2007-04-27 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| MXPA05003866A (es) | 2002-10-11 | 2005-06-22 | Pfizer | Derivados de indol como agonistas beta-2. |
| AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
| DE60320007T2 (de) | 2002-10-28 | 2009-06-18 | Glaxo Group Ltd., Greenford | Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| PL378245A1 (pl) | 2003-01-09 | 2006-03-20 | Astellas Pharma Inc. | Pochodne pirolopirydazyny |
| AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| ATE421322T1 (de) | 2003-04-04 | 2009-02-15 | Novartis Pharma Gmbh | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege |
| AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| ES2329133T3 (es) | 2003-05-28 | 2009-11-23 | Theravance, Inc. | Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos. |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| ES2298757T3 (es) | 2003-06-04 | 2008-05-16 | Pfizer Inc. | Derivados de z-amino-piridina como agonistas de adrecorreceptores beta-2. |
| JP2006527207A (ja) | 2003-06-11 | 2006-11-30 | メルク フロスト カナダ リミテツド | 7−(1,3−チアゾール−2−イル)チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用 |
| WO2004111044A1 (en) | 2003-06-17 | 2004-12-23 | Glenmark Pharmaceuticals Ltd. | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| ITMI20031451A1 (it) | 2003-07-16 | 2005-01-17 | Zambon Spa | Derivati diidro-ftalazinici inibitori della fosfodiesterasi 4 |
| EP1658270A1 (en) | 2003-07-31 | 2006-05-24 | ALTANA Pharma AG | Novel 6-phenylphenantridines |
| JP2007500686A (ja) | 2003-07-31 | 2007-01-18 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規の6−フェニルフェナントリジン |
| US7465746B2 (en) * | 2003-08-15 | 2008-12-16 | Merck & Co., Inc. | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US8241489B2 (en) | 2003-12-19 | 2012-08-14 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ2受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| ME00557A (en) | 2004-01-22 | 2011-12-20 | Sulfonamide derivatives for the treatment of diseases | |
| CA2553789C (en) | 2004-01-22 | 2011-07-19 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
| DE102004003428A1 (de) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| DE502005010170D1 (de) | 2004-02-14 | 2010-10-14 | Boehringer Ingelheim Pharma | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel |
| MXPA06009892A (es) | 2004-03-10 | 2007-03-01 | Altana Pharma Ag | Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4). |
| CA2558390A1 (en) | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
| EP1574501A1 (en) | 2004-03-11 | 2005-09-14 | Pfizer Limited | Quinolinone derivatives, pharmaceutical compositions containing them and their use |
| US20070225308A1 (en) | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| EA200601510A1 (ru) | 2004-03-17 | 2007-04-27 | Пфайзер Инк. | Производные фенилэтаноламина в качестве бета-2-агонистов |
| US7244728B2 (en) | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
| EP1732925A1 (en) | 2004-03-17 | 2006-12-20 | Altana Pharma AG | Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors |
| PL1730103T3 (pl) | 2004-03-23 | 2010-10-29 | Pfizer | Pochodne formamidu użyteczne jako adrenoreceptor |
| US20050215542A1 (en) | 2004-03-23 | 2005-09-29 | Pfizer Inc | Compounds for the treatment of diseases |
| AU2005225638A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Inc. | Compounds for the treatment of diseases |
| WO2005092860A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| EP1730104A1 (en) | 2004-04-02 | 2006-12-13 | Glaxo Group Limited | Chemical process and new crystalline form |
| US20050239778A1 (en) | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
| DE102004019539A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
| US7307076B2 (en) | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
| US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
| US20050256115A1 (en) | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| EP1751086A2 (en) | 2004-06-03 | 2007-02-14 | Theravance, Inc. | DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS |
| JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
| GB0416397D0 (en) | 2004-07-22 | 2004-08-25 | Glaxo Group Ltd | Pharmaceutical formulations |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| US7838597B2 (en) | 2004-08-20 | 2010-11-23 | Sekisui Specialty Chemicals America, Llc | Fluid loss concentrate for hydraulic cement |
| EP1786762A2 (en) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EA200701260A1 (ru) | 2005-01-11 | 2008-02-28 | Глаксо Груп Лимитед | Циннаматные соли бета-2 адренергического агониста |
| DE602006003432D1 (de) * | 2005-05-13 | 2008-12-11 | Lilly Co Eli | Latoren des androgenrezeptors |
| SI2206707T1 (sl) * | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| EP2331499B1 (en) * | 2008-08-19 | 2016-09-21 | Janssen Pharmaceutica NV | Cold menthol receptor antagonists |
| TW201022233A (en) * | 2008-11-04 | 2010-06-16 | Organon Nv | (Pyrrolidin-2-yl)phenyl derivatives |
| WO2010117787A2 (en) * | 2009-03-30 | 2010-10-14 | The Brigham And Women's Hospital, Inc. | Inhibiting eph b-3 kinase |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| UY33597A (es) * | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
-
2012
- 2012-02-23 BR BR112013021638A patent/BR112013021638A2/pt not_active IP Right Cessation
- 2012-02-23 CN CN201280019867.0A patent/CN103492384B/zh not_active Expired - Fee Related
- 2012-02-23 US US14/000,578 patent/US9102671B2/en active Active
- 2012-02-23 CA CA2828219A patent/CA2828219A1/en not_active Abandoned
- 2012-02-23 SG SG2013062179A patent/SG192795A1/en unknown
- 2012-02-23 ES ES12708450.7T patent/ES2551592T3/es active Active
- 2012-02-23 MA MA36253A patent/MA34969B1/fr unknown
- 2012-02-23 GE GEAP201213241A patent/GEP20156285B/en unknown
- 2012-02-23 AP AP2013007103A patent/AP2013007103A0/xx unknown
- 2012-02-23 PH PH1/2013/501758A patent/PH12013501758A1/en unknown
- 2012-02-23 EP EP12708450.7A patent/EP2678338B1/en active Active
- 2012-02-23 EA EA201391230A patent/EA201391230A1/ru unknown
- 2012-02-23 PE PE2013001975A patent/PE20140378A1/es not_active Application Discontinuation
- 2012-02-23 JP JP2013555571A patent/JP5959541B2/ja not_active Expired - Fee Related
- 2012-02-23 MX MX2013009767A patent/MX2013009767A/es not_active Application Discontinuation
- 2012-02-23 KR KR1020137025068A patent/KR20140014184A/ko not_active Withdrawn
- 2012-02-23 AU AU2012220572A patent/AU2012220572A1/en not_active Abandoned
- 2012-02-23 WO PCT/US2012/026377 patent/WO2012116217A1/en not_active Ceased
-
2013
- 2013-08-15 IL IL227987A patent/IL227987A0/en unknown
- 2013-08-19 ZA ZA2013/06221A patent/ZA201306221B/en unknown
- 2013-08-19 TN TNP2013000348A patent/TN2013000348A1/fr unknown
- 2013-08-22 CO CO13199508A patent/CO6751270A2/es unknown
- 2013-08-22 CL CL2013002430A patent/CL2013002430A1/es unknown
- 2013-08-23 CU CU2013000115A patent/CU20130115A7/es unknown
- 2013-08-23 GT GT201300209A patent/GT201300209A/es unknown
- 2013-08-23 DO DO2013000192A patent/DOP2013000192A/es unknown
- 2013-08-23 NI NI201300073A patent/NI201300073A/es unknown
- 2013-08-26 CR CR20130410A patent/CR20130410A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2010048314A1 (en) * | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Non-Patent Citations (4)
| Title |
|---|
| Gold(I)-Catalyzed Domino Ring-Opening Ring-Closing Hydroamination of Methylenecyclopropanes (MCPs) with Sulfonamides: Facile Preparation of Pyrrolidine Derivatives;Min Shi,等;《ORGANIC LETTERS》;20060812;第8卷(第18期);4043-4046 * |
| Halogen- and N-Haloimide-Promoted Homo- and Heterocoupling of α-(N-Carbamoyl)alkylcuprates and α-(Alkoxy)alkylcuprates;R. Karl Dieter,等;《J. Org. Chem.》;20040320;第69卷;2867-2870 * |
| Hammett Correlation of Nornicotine Analogues in the Aqueous Aldol Reaction:Implications for Green Organocatalysis;Claude J. Rogers,等;《J. Org. Chem.》;20050331;第70卷;3705-3708 * |
| Quantitative Structure-Activity Relationships of Nicotine Analogues as Neuronal Nicotinic Acetylcholine Receptor Ligands;Ki Hwan Kim,等;《Bioorganic & Medicinal Chemistry》;19961231;第4卷(第12期);2211-2217 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013021638A2 (pt) | 2016-08-02 |
| DOP2013000192A (es) | 2014-01-31 |
| CO6751270A2 (es) | 2013-09-16 |
| WO2012116217A1 (en) | 2012-08-30 |
| KR20140014184A (ko) | 2014-02-05 |
| ES2551592T3 (es) | 2015-11-20 |
| TN2013000348A1 (en) | 2015-01-20 |
| IL227987A0 (en) | 2013-09-30 |
| MA34969B1 (fr) | 2014-03-01 |
| GT201300209A (es) | 2015-06-02 |
| NI201300073A (es) | 2013-12-17 |
| JP5959541B2 (ja) | 2016-08-02 |
| ZA201306221B (en) | 2014-04-30 |
| SG192795A1 (en) | 2013-09-30 |
| GEP20156285B (en) | 2015-05-11 |
| JP2014506599A (ja) | 2014-03-17 |
| EP2678338A1 (en) | 2014-01-01 |
| EP2678338B1 (en) | 2015-09-09 |
| CU20130115A7 (es) | 2013-12-27 |
| PE20140378A1 (es) | 2014-03-28 |
| PH12013501758A1 (en) | 2013-10-14 |
| US20130331397A1 (en) | 2013-12-12 |
| US9102671B2 (en) | 2015-08-11 |
| AP2013007103A0 (en) | 2013-09-30 |
| CL2013002430A1 (es) | 2013-11-29 |
| CR20130410A (es) | 2013-10-17 |
| EA201391230A1 (ru) | 2014-01-30 |
| CN103492384A (zh) | 2014-01-01 |
| AU2012220572A1 (en) | 2013-08-29 |
| CA2828219A1 (en) | 2012-08-30 |
| MX2013009767A (es) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5959541B2 (ja) | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン | |
| CN112105419B (zh) | 稠环化合物 | |
| US8637516B2 (en) | Compounds and compositions as TRK inhibitors | |
| CA2890876C (en) | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors | |
| CN105732636B (zh) | 杂芳化合物及其在药物中的应用 | |
| CA2976741C (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| AU2012288626B2 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | |
| RU2672722C2 (ru) | Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp | |
| WO2012034095A1 (en) | Compounds and compositions as trk inhibitors | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| RS60468B1 (sr) | Nova jedinjenja | |
| KR20150090044A (ko) | 아자퀴나졸린 카복사미드 유도체 | |
| TW202321239A (zh) | 作為hpk1抑制劑用於治療癌症之經取代的吡𠯤—2—甲醯胺 | |
| AU2021249109A1 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | |
| AU2018339722B2 (en) | Compound having ERK kinase inhibitory activity and use thereof | |
| CN115850301B (zh) | 吡唑酮类化合物及其组合物和用途 | |
| AU2013204962C1 (en) | Polymorphic form of a mesylate salt of n-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide | |
| AU2015261672A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160107 Address after: British Bermuda, Hamilton Applicant after: Novartis international pharmaceuticals Ltd. Address before: British Bermuda, Hamilton Applicant before: IRM LLC Effective date of registration: 20160107 Address after: Basel, Switzerland Applicant after: NOVARTIS AG Address before: British Bermuda, Hamilton Applicant before: Novartis international pharmaceuticals Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160511 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |